tbuckley/cabot-search huggingface dataset:
Better Cholera Counts Through Machine Learning Models
Authors: Jennifer Abbasi
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cardiovascular events in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors: A systematic review and meta-analysis.
Authors: Chatree Chai-Adisaksopha, Christopher Michael Hillis, Wilson Lam
Journal: Journal of Clinical Oncology (2015)

7056 Background: Tyrosine kinase inhibitors (TKIs) have dramatically improved survival for patients with chronic myelogenous leukemia (CML). However, there are growing evidences that TKIs may be associated with an increased risk of cardiovascular events. Methods: We searched MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) databases. Included studies were: (1) randomized controlled trials or cohort studies of adult patients ( ≥ 18 years) treated with TKIs for chronic phase or accelerated phase CML, (2) studies that reported at least one cardiovascular outcome (peripheral arterial occlusive disease (PAOD), ischemic heart disease or stroke/TIA). The primary outcome of this review were a composite of major cardiovascular events. The pooled incidences of cardiovascular events with corresponding 95% confidence intervals [CI] were performed using a single-proportion random-effects model. The pooled risk ratio (RR) with 95% CIs was calculated using a Mantel-Haenszel random-effects model to compare the effect between nilotinib and imatinib. Results: We identified 32 studies enrolling 16,218 patients (20 studies investigated nilotinib, 12 imatinib, 4 ponatinib, 1 dasatinib and 1 bosutinib). The pooled incidence rates (95% CI) of cardiovascular events were 8% (6-10%) for nilotinib, 1% (0-1%) for imatinib, 2% (1-2%) for dasatinib, 10% (5-16%) for ponatinib and 13% (11-16%) for bosutinib and 6% (3-10%) for non-TKI studies. The direct comparison between nilotinib and imatinib suggested that nilotinib treatment was associated with a significantly increased risk of the cardiovascular events (RR 1.6; 95%CI 1.4-1.8). Conclusions: Here, we evaluated the pooled estimates of the incidence of cardiovascular events in CML patients treated with TKIs. The pool proportions suggested that, when compared to non-TKI treated patients, patients who received imatinib and dasatinib had lesser cardiovascular events, whereas the incidence was greater among patients receiving nilotinib, ponatinib and bosutinib.
Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases
Authors: Aki Morikawa, Elisa de Stanchina, Elena Pentsova, Margaret M. Kemeny, Bob T. Li, Kendrick Tang, Sujata Patil, Martin Fleisher, Catherine Van Poznak, Larry Norton, Andrew D. Seidman
Journal: Clinical Cancer Research (2019)

Abstract Purpose: Lapatinib and capecitabine cross the blood–tumor barrier in breast cancer brain metastasis but have modest clinical efficacy. Administration of high-dose tyrosine kinase inhibitor has been evaluated in brain metastases and primary brain tumors as a strategy to improve drug exposure in the central nervous system (CNS). We derived a rational drug scheduling of intermittent high-dose lapatinib alternating with capecitabine based on our preclinical data and Norton–Simon mathematical modeling. We tested this intermittent, sequential drug schedule in patients with breast cancer with CNS metastasis. Patients and Methods: We conducted a phase I trial using an accelerated dose escalation design in patients with HER2-positive (HER2+) breast cancer with CNS metastasis. Lapatinib was given on day 1–3 and day 15–17 with capecitabine on day 8–14 and day 22–28 on an every 28-day cycle. Lapatinib dose was escalated, and capecitabine given as a flat dose at 1,500 mg BID. Toxicity and efficacy were evaluated. Results: Eleven patients were enrolled: brain only (4 patients, 36%), leptomeningeal (5 patients, 45%), and intramedullary spinal cord (2 patients, 18%). Grade 3 nausea and vomiting were dose-limiting toxicities. The MTD of lapatinib was 1,500 mg BID. Three patients remained on therapy for greater than 6 months. Conclusions: High-dose lapatinib is tolerable when given intermittently and sequentially with capecitabine. Antitumor activity was noted in both CNS and non-CNS sites of disease. This novel administration regimen is feasible and efficacious in patients with HER2+ breast cancer with CNS metastasis and warrants further investigation.
SAT-335-A simple biomarker panel predictive of advanced fibrosis in patients with non-alcoholic steatohepatitis
Authors: Zobair Younossi, Azza Karrar, Maria Stepanova, Brian Lam, Sean Felix, Thomas Jeffers, Samuel Hellings, Elizabeth Brown, Thomas Spires, Melissa Yarde, Yi Luo, Anthony Sanfiz, Leonid Zhelnin, Gabor Jarai, Mary Ellen Cvijic, Edgar Charles, Sumanta Mukherjee, Lei Zhao, David Gordon, Fatema Nader, Zachary Goodman
Journal: Journal of Hepatology (2019)
Context-dependent EMT programs in cancer metastasis
Authors: Nicole M. Aiello, Yibin Kang
Journal: The Journal of Experimental Medicine (2019)

Epithelial–mesenchymal transition (EMT) is a developmental process whereby stationary, adherent cells acquire the ability to migrate. EMT is critical for dramatic cellular movements during embryogenesis; however, tumor cells can reactivate EMT programs, which increases their aggressiveness. In addition to motility, EMT is associated with enhanced stem cell properties and drug resistance; thus it can drive metastasis, tumor recurrence, and therapy resistance in the context of cancer. However, the precise requirements for EMT in metastasis have not been fully delineated, with different tumor types relying on discrete EMT effectors. Most tumor cells do not undergo a full EMT, but rather adopt some qualities of mesenchymal cells and maintain some epithelial characteristics. Emerging evidence suggests that partial EMT can drive distinct migratory properties and enhance the epithelial-mesenchymal plasticity of cancer cells as well as cell fate plasticity. This review discusses the diverse regulatory mechanisms and functional consequences of EMT, with an emphasis on the importance of partial EMT.
TCTAP A-033 The Comparison of Mortality in Patients with Acute Myocardial Infarction Associated with or Without Sepsis
Authors: En-Shao Liu, Cheng-Hung Chiang, Wang-Ting Hung, Pei-Ling Tang, Cheng Chung Hung, Shu-Hung Kuo, Jin-Shiou Yang, Chun-Peng Liu, Yao-shen Chen, Guang-Yuan Mar, Wei-Chun Huang
Journal: Journal of the American College of Cardiology (2019)
SAT-475-Clinical validation of the role of contrast-enhanced ultrasound in the EASL guidelines for the diagnosis of hepatocellular carcinoma
Authors: Lorenzo Mulazzani, Vito Sansone, Luca Giordano, Chiara Di Bonaventura, Alice Giamperoli, Angelo Cimino, Fabio Piscaglia
Journal: Journal of Hepatology (2019)
Acupuncture Versus Cognitive Behavioral Therapy for Insomnia in Cancer Survivors: A Randomized Clinical Trial
Authors: Sheila N Garland, Sharon X Xie, Kate DuHamel, Ting Bao, Qing Li, Frances K Barg, Sarah Song, Philip Kantoff, Philip Gehrman, Jun J Mao
Journal: JNCI Journal of the National Cancer Institute (2019)

Abstract Background Insomnia is a common and debilitating disorder experienced by cancer survivors. Although cancer survivors express a preference for using nonpharmacological treatment to manage insomnia, the comparative effectiveness between acupuncture and Cognitive Behavioral Therapy for Insomnia (CBT-I) for this disorder is unknown. Methods This randomized trial compared 8 weeks of acupuncture (n = 80) and CBT-I (n = 80) in cancer survivors. Acupuncture involved stimulating specific points on the body with needles. CBT-I included sleep restriction, stimulus control, cognitive restructuring, relaxation training, and education. We measured insomnia severity (primary outcome), pain, fatigue, mood, and quality of life posttreatment (8 weeks) with follow-up until 20 weeks. We used linear mixed-effects models for analyses. All statistical tests were two-sided. Results The mean age was 61.5 years and 56.9% were women. CBT-I was more effective than acupuncture posttreatment (P &amp;lt; .001); however, both acupuncture and CBT-I produced clinically meaningful reductions in insomnia severity (acupuncture: −8.31 points, 95% confidence interval = −9.36 to −7.26; CBT-I: −10.91 points, 95% confidence interval = −11.97 to −9.85) and maintained improvements up to 20 weeks. Acupuncture was more effective for pain at the end of treatment; both groups had similar improvements in fatigue, mood, and quality of life and reduced prescription hypnotic medication use. CBT-I was more effective for those who were male (P &amp;lt; .001), white (P = .003), highly educated (P &amp;lt; .001), and had no pain at baseline (P &amp;lt; .001). Conclusions Although both treatments produced meaningful and durable improvements, CBT-I was more effective and should be the first line of therapy. The relative differences in the comparative effectiveness between the two interventions for specific groups should be confirmed in future adequately powered trials to guide more tailored interventions for insomnia.
TCTAP A-002 Evaluation of Vascular Response and Healing After Implantation of Tetrilimus Everolimus-eluting Coronary Stent by Optical Coherence Tomography (EVER-OCT): 3 and 6 Month Serial Analysis
Authors: Upendra Kaul, Rajpal K. Abhaichand, Atul Abhyankar, Ajit Bhagwat, G. Sengottuvelu, C.G. Bahuleyan, Priyadarshini Arambam, Diana Yumnam
Journal: Journal of the American College of Cardiology (2019)
THU-141-Efficacy and safety of elbasvir/grazoprevir in a large real-life cohort of HCV-infected patients
Authors: Martina Gambato, Angiola Spinetti, Luisa Pasulo, Roberta D’ambrosio, Massimo Puoti, Monica Schiavini, Paolo Fabris, Paolo Sacchi, Roberto Gulminetti, Giada Carolo, Piergiorgio Scotton, Caterina Pozzan, Maria Vinci, Mauro Viganò, Salvatore Lobello, Massimo Giovanni Zuin, Alessio Aghemo, Maria Grazia Rumi, Maurizio Carrara, Vinicio Manfrin, Caterina Uberti-Foppa, Sandro Panese, Francesca Cattelan, Veronica Paon, Angelo Pan, Ombretta Spinelli, Antonella d'Arminio Monforte, Agostino Colli, Giancarlo Spinzi, Francesco Paolo Russo, Liliana Chemello, Valter Vincenzi, Paolo Antonio Grossi, Elisabetta Buscarini, Giovanna Cardaci, Alessandro Soria, Barbara Menzaghi, Monia Mendeni, Elisabetta Degasperi, Roberta Soffredini, Maria Colpani, Laura Comi, Valentina Zuccaro, Serena Zaltron, ANDREA Gori, Paolo Del Poggio, Alessia Giorgini, Andrea Capretti, massimo Memoli, Marie Graciella Pigozzi, Maria Cristina Rossi, Luisa Cavalletto, Franco Capra, Alberto Colombo, Clara Dibenedetto, Simona Landonio, Franco Noventa, Pietro Lampertico, Francesco Castelli, Alfredo Alberti, Stefano Fagiuoli
Journal: Journal of Hepatology (2019)
TTF1 status in non-small cell lung cancer adenocarcinoma: A prognostic factor
Authors: J.F. Cordoba Ortega, A. Salud, S. Morales, J. Veas, A. Rodriguez
Journal: Annals of Oncology (2019)

Background: Patients with thyroid transcription factor 1 (TTF1) negative lung adenocarcinoma (ADC) have been reported to have a worse prognosis and to lack epidermal growth factor receptor (EGFR) mutations. The aim of this study was to analyse the prognostic significance of TTFI status in a series of tumor samples from patients with clinically confirmed lung adenocarcinoma. Methods: A real-world data study of TTF1-negative ADC was performed in all lung cancer patients diagnosed in the University Hospital of Lleida from January 2011 to December 2016, using TTF1 clone 8G7G3/1(DAKO®). Each patient's clinical history, pathology specimens and molecular results were noted. The control group consisted of 231 patients with TTF1 positive lung ADC. Results: Three hundred and thirty four (334) patients with ADC were identified; TTF1 results were available in 258 (77,2%) cases. Of these, 27 (10,4%) patients were identified with TTF1-negative ADC (74% males). The median age of these patients was 66 years and their smoking history was as follows: 55,5% former smoker, 29,6% ex smokers and 14,8% never smokers. The clinical stages were as follows: stage I or II (n = 3 [11%]), stage III (n = 4 [14,8%]) and stage IV (n = 20 [74%]). Patients' mean survival was 7,6 vs 24,4 months in ADC TTF1-negative patients versus TTF1-postive patients (P = 0,00001). When compared with the control group, TTF1-negative patients had shorter overall survival (P = 0,00001), regardless of whether patients were treated with radical or palliative intent: 34,4 vs 10, months P = 0,00001 (radical treatment) and 14,6 vs 6,7 months P = 0,007 (palliative intent). EGFR mutations were less frequent (P = 0,046) in TTF-negative tumors compared to the control group (5,5% vs 25,3%). Conclusions: Patients with TTF1-negative NSCLC ADC have worse overall survival, regardless of treatment intention, and a lower frequency of EGFR mutations. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
Widespread gene transfer to malignant gliomas with In vitro-to-In vivo correlation
Authors: Karina Negron, Namir Khalasawi, Billy Lu, Chi-Ying Ho, Jason Lee, Siddharth Shenoy, Hai-Quan Mao, Tza-Huei Wang, Justin Hanes, Jung Soo Suk
Journal: Journal of Controlled Release (2019)
Abstract 18170: Role of Ketohexokinase in Fructose-Mediated Insulin Resistance and Endothelial Dysfunction
Authors: Asjad Visnagri, Hema Viswambharan, Yilizila Abudushalamu, Luke Morris, Nadira Yuldasheva, David Bonthron, Mark Kearney, Aruna Asipu
Journal: Circulation (2017)

Introduction: Diet-related cardiovascular disease is a major cause of mortality. Over-consumption of fructose, widely used in soft drinks, results in adverse metabolic effects, including insulin re...
Circular RNAs in Cancer: emerging functions in hallmarks, stemness, resistance and roles as potential biomarkers
Authors: Min Su, Yuhang Xiao, Junliang Ma, Yanyan Tang, Bo Tian, Yuqin Zhang, Xu Li, Zhining Wu, Desong Yang, Yong Zhou, Hui Wang, Qianjin Liao, Wenxiang Wang
Journal: Molecular Cancer (2019)

Circular RNAs (circRNAs) are a class of RNA molecules with closed loops and high stability. CircRNAs are abundantly expressed in eukaryotic organisms and exhibit both location- and step-specificity. In recent years, circRNAs are attracting considerable research attention attributed to their possible contributions to gene regulation through a variety of actions, including sponging microRNAs, interacting with RNA-binding proteins, regulating transcription and splicing, and protein translation. Growing evidence has revealed that circRNAs play critical roles in the development and progression of diseases, especially in cancers. Without doubt, expanding our understanding of circRNAs will enrich knowledge of cancer and provide new opportunities for cancer therapy. In this review, we provide an overview of the characteristics, functions and functional mechanisms of circRNAs. In particular, we summarize current knowledge regarding the functions of circRNAs in the hallmarks, stemness, resistance of cancer, as well as the possibility of circRNAs as biomarkers in cancer.
Abstract 14751: Rising NT-probnp Levels Are Associated With Reduced Survival in Patients With Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) and Reduced Ejection Fraction (HFrEF)
Authors: Thejaswi Poonacha, Nishant Sahni
Journal: Circulation (2015)

Objective/Aim: To determine the impact of temporal trends in NT-proBNP levels on 6-month survival in HFpEF and HFrEF. Introduction: High levels NT-proBNP are associated with reduced survival patients with heart failure. However, it remains to be conclusively demonstrated that in addition to absolute NT-proBNP levels, temporal trends in NT-proBNP level in individual patients also impact survival. Methods: We conducted a retrospective study on a cohort of 8255 patients who had at least one admission to the hospital with diagnoses of heart failure between Jan 2011 and Dec 2014.Using EMR data, we created a dataset that included all NT-proBNP levels obtained on these patients at any time during the study interval, irrespective of whether the test was done in a hospital or clinic setting. We used text-mining techniques to extract the numerical value of ejection fraction from reports of echocardiograms obtained during this interval. We performed multivariate regression analysis to identify factors independently associated with six-month survival. In addition, we also constructed Kaplan-Meier curves to determine the impact of temporal trends in NT-proBNP in individual patients on 6-month survival. Results: For patients with HFpEF (EF&gt;45%), and HFrEF, maximum NT-proBNP levels achieved during the study period were associated with higher odds of 6-month mortality (p &lt;0.05). Independent of the absolute NT-proBNP level, patients with a rising BNP level had higher odds of 6-month mortality (Odds ratio (OR): 1.29-1.52) as compared to patients with stable or declining NT-proBNP levels. This was true both for patients with HFpEF (OR: 1.30-1.66) and for patients with HFrEF (OR: 1.13-1.43). Kaplan-Meier survival curves demonstrated significantly higher 6 month survival rates for patients that did not have a net rise in NT-proBNP levels for patients both the subtypes of HF. (p &lt;0.05) Conclusion: A rising NT-proBNP level is associated with higher 6-month mortality in patients with HFpEF as well as HFrEF. This may indicate that the use of NT-proBNP guided therapy for patients with heart failure merits further study.
Kurt Karl Stephan Semm, 1927 - 2003
Journal: Endoscopy (2003)

Kurt Karl Stephan Semm died in Tucson, Arizona, on 16 July 2003, aged 76. He achieved worldwide recognition as a gynecologist and as Director of the Department of Gynecology at the University of Kiel (Germany), above all by introducing and contributing to the subsequent widespread application of laparoscopic surgery in the abdomen and pelvis - a field in which he initially had to struggle against a considerable amount of prejudice. Even in his home city of Kiel, it was initially difficult to find acceptance for the technique he termed “pelviscopy”. Kurt Semm was not only an important physician, but also a medical technologist who founded his own company to design and manufacture numerous devices aimed at improving laparoscopic surgical techniques. He was a vivacious man who fought with enthusiasm and persuasiveness for new ideas he recognized as right. He received numerous awards, among which honorary doctorates from several universities deserve particular mention. He was for many years a member of the Advisory Board of the German Society for Endoscopy and Imaging Procedures, and served as its President in 1970, 1978 and 1990. We at Endoscopy are grateful to him for his commitment and dedicated work for the journal as an Associate Editor. As a human being, a physician, and as an innovative, creative, and scientifically oriented endoscopist and surgeon, Kurt Semm will not be forgotten. Meinhard Classen
THU-363-Lipid nanoparticle pre-treatment improves adeno-associated virus diffusion in the primate liver and enables an increase of therapeutic transgene expression
Authors: Karin L Kwikkers, Lukas Schwarz, Johannes de Laat, Anna Majowicz, Paula S. Miranda, Alexander W. Gielen, Martin de Haan, Harald Petry, Sander van Deventer, Valerie Ferreira
Journal: Journal of Hepatology (2019)
PS-197-Heterozygous alphal-antitrypsin deficiency (Pi*MZ) is associated with increased liver stiffness and elevated liver enzymes in a multi-center European cohort
Authors: Carolin Victoria Heimes, Karim Hamesch, Linda S. Moeller, Mattias Mandorfer, Matthias Reichert, Arslanow Anita, Malin Fromme, Vivien Woditsch, Cecilia Lindhauer, Jessica Voss, Igor Spivak, robert bals, Sabina Janciauskiene, Vitor Pereira, Joana Carvão, William JH Griffiths, Frank Lammert, Aleksander Krag, Michael Trauner, Christian Trautwein, Pavel Strnad
Journal: Journal of Hepatology (2019)
A multi-center prospective study of radiofrequency ablation without surgical excision for small breast carcinomas.
Authors: Takayuki Kinoshita, Naohito Yamamoto, Tomomi Fujisawa, Masato Takahashi, Hiroyoshi Doihara, Kenjiro Aogi, Noriaki Wada
Journal: Journal of Clinical Oncology (2015)

e12043 Background: The most promising nonsurgical ablation technique is radiofrequency ablation (RFA). Our preliminary studies of RFA followed by standard surgical resection have indicated that this technique is effective for small ( ≤ 2cm) breast tumors without extensive intraductal components (EIC). Methods: To determine if RFA is oncologically and cosmetically appropriate for the local treatment of primary breast carcinoma, this multi-center prospective study used RFA as the sole local treatment of breast tumors ≤ 1.0cm in size on ultrasound and MRI. Exclusion criteria include receiving of preoperative chemotherapy, or the presence of invasive lobular carcinoma or invasive ductal carcinoma with suspicious EIC. After confirmation that the standard baseline core biopsy for diagnosis and measurement of tumors markers (ER, PgR, HER-2/neu and Ki-67) have been obtained, the patients were scheduled RFA. All patients received adjuvant radiation therapy. The use and choice of systemic therapy will be based on the information from the baseline biopsy specimens. 58 patients with small tumors that are clearly identifiable and measurable by ultrasound and MRI were enrolled. The response to ablation was evaluated with vacuum-assisted biopsies and imaging studies every 3 months during the first year. The long-term outcomes were assessed using imaging studies every 6 months after 5 years. Results: Of the 58 patients who participated in this study, 55 completed the protocol. In 48 of the 55 (87%) treated patients, successful tumor ablation, as determined by negative findings on vacuum-assisted biopsies and imaging studies, was confirmed. The remaining 7 patients with biopsies positive for residual tumor underwent surgical resection. There were no local or distant recurrences in treated 55 patients with a median follow up of 37 months (range 24-61 months). Conclusions: RFA can be safely used alone in patients with small breast tumors, provided that local tumor control must be regularly assessed by image-guided vacuum-assisted biopsies after ablation. RFA has several potential advantages over lumpectomy for the treatment of early stage breast cancer. Clinical trial information: UMIN000008608.
The Dark Side of Innate Immunity Fosters Tumor Growth and Offers New Diagnostic
Authors: Ennio Carbone
Journal: Clinical Cancer Research (2019)

So far, the tumor's immune landscape has been related mainly to the adaptive immune cell infiltrate. The possibility of using tumor-infiltrating innate immune cells as the source for prognostic markers and their role in immune checkpoint therapy have been neglected. Unraveling these aspects may lead to new immune therapy interventions.See related article by Duan et al., p. 3304.